Taysha Gene Therapies, Inc.
General ticker "TSHA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Taysha Gene Therapies, Inc. follows the US Stock Market performance with the rate: 57.8%.
Estimated limits based on current volatility of 4.8%: low 5.60$, high 6.16$
Factors to consider:
- Total employees count: 99 (+35.6%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Need for successful capital raising, Limited operating history, Regulatory and compliance, Clinical trial failure
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.25$, 8.10$]
- 2026-12-31 to 2027-12-31 estimated range: [2.59$, 6.61$]
Financial Metrics affecting the TSHA estimates:
- Positive: with PPE of -16.6 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of -0.03 > -0.60
- Negative: Shareholder equity ratio, % of 71.93 > 64.23
- Negative: negative Net income
Short-term TSHA quotes
Long-term TSHA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $15.45MM | $8.33MM | $9.77MM |
| Operating Expenses | $87.89MM | $99.79MM | $120.27MM |
| Operating Income | $-72.44MM | $-91.46MM | $-110.50MM |
| Non-Operating Income | $-39.13MM | $2.13MM | $1.50MM |
| Interest Expense | $5.00MM | $0.10MM | $0.06MM |
| R&D Expense | $56.78MM | $66.00MM | $86.40MM |
| Income(Loss) | $-111.57MM | $-89.33MM | $-109.00MM |
| Net Income(Loss)* | $-111.57MM | $-89.30MM | $-109.00MM |
| Stockholders Equity | $74.94MM | $71.53MM | $246.94MM |
| Assets | $172.73MM | $160.36MM | $343.32MM |
| Operating Cash Flow | $-73.02MM | $-81.22MM | $-93.09MM |
| Capital expenditure | $7.37MM | $0.37MM | $0.74MM |
| Investing Cash Flow | $-7.35MM | $-0.36MM | $-0.60MM |
| Financing Cash Flow | $136.39MM | $76.68MM | $274.59MM |
| Earnings Per Share** | $-0.96 | $-0.36 | $-0.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.